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Case presentation
A 36-yr-old man was admitted to the hospital for the
eighth time because of confusion, lethargy, nausea, and
vomiting of three weeks duration; he had been discharged
from the hospital only three and one-half weeks earlier.
The patient is a known alcoholic with a daily intake of
approximately one quart of wine and one fifth of whiskey
or vodka for at least eight years. Four years ago, he was
evaluated at another hospital for a seizure disorder thought
to be due to alcohol withdrawal. Three years ago, he was
admitted to the New England Medical Center Hospital for
the first time for nausea, vomiting, abdominal pain, sei-
zures, and fever. Examination at that time revealed normal
blood pressure, asterixis, and an enlarged liver; he had no
ascites, edema, or peripheral neuropathy. The weight was
75 kg. The hematocrit was 25%. Laboratory findings at that
time were: serum electrolytes, normal; blood urea nitrogen
(BUN), 5 mg; serum creatinine, 1.2 mg; serum bilirubin, 2
mg; serum albumin, 4 g/100 ml; and alkaline phosphatase,
6.3 Bodansky U. Hemoglobin electrophoresis revealed
sickle cell trait. Upper gastrointestinal series revealed
"duodenitis" without a definite ulcer crater. An i.v. uro-
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gram was normal. He was treated with folic acid, thiamine,
multivitamins, antacids, chlordiazepoxide, and phenytoin.
During the next three years, the patient was readmitted
several times. A liver biopsy specimen obtained two years
prior to the present hospitalization revealed hemosiderosis,
mild to moderate cirrhosis, and mild alcoholic hepatitis.
During one representative admission, initial laboratory
findings were: BUN, 45 mg; serum creatinine, 4.5 mgIlOO
ml; sodium, 136 mEq; potassium 2.6 mEq; chloride, 85
mEq; and total carbon dioxide content, 36 mEq/liter. Diar-
rhea, thought to be related to lactulose therapy, resulted in
a transient fall in the total carbon dioxide content to 12
mEq/Iiter. By the time of discharge, the serum creatinine
had fallen to 0.8 mgIlOO ml; the serum sodium was 138
mEq, potassium was 5 mEq, chloride was 105 mEq, and
total carbon dioxide content was 20 mEq/liter.
Three months prior to the present hospitalization, the
patient was admitted because of confusion. Weight was
63.9 kg; ascites and edema were noted. The bilirubin was
7.3 mgIlOO ml. Serum electrolytes were: sodium,133 mEq;
potassium, 2.4 mEq; chloride, 72 mEq/Iiter. Total carbon
dioxide content was 43 mEq/liter. At the time of admission,
the BUN was 88 mg, and the serum creatinine was 3.3 mgI
100 ml; by the time of discharge, they were 31 and 2.3 mgI
100 ml, respectively. The mental confusion thought to be
due to hepatic encephalopathy, disappeared completely
before discharge. The patient was discharged on a regimen
of spironolactone, folic acid, thiamine, and phenytoin.
Six weeks prior to the present admission, the patient
was again hospitalized for mental confusion, nausea, vom-
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iting, and weakness. Blood pressure was 90/70 mm Hg,
weight was 58.8 kg, and there was massive ascites. The
patient was icteric; asterixis and a peripheral neuropathy
were demonstrated. The serum concentration of sodium
was 141 mEq, potassium was 2.6 mEq, chloride was 66
mEq, and the total carbon dioxide content was 53 mEq/
liter. Arterial blood findings were: pH, 7.6; arterial oxygen
tension (P02), 51 mm Hg; and arterial carbon dioxide ten-
sion (Pco2), 53 mm Hg. Random urinary values for electro-
lytes concentrations were: sodium, 60 mEq; and chloride 0
mEq/liter; the patient was not receiving diuretics at this
time. At the time of admission, the BUN was 60 mg, and
the serum creatinine was 5 mg/l00 ml; before discharge, it
was 53 and 3.9 mg/tOO ml. respectively. Upper gastrointes-
tinal series was negative on two occasions. Renal echo-
gram revealed the kidneys to be of normal size; there was
no evidence of obstruction. The serum electrolytes and
acid-base equilibrium returned toward normal. While the
patient was being treated with nasogastric suction, how-
ever, the total carbon dioxide content rose to 49 mEq/liter,
and the arterial Pco2 rose to 67 mm Hg. Arginine hydro-
chloride (approximately 150 mEq, in 300 cc) was adminis-
tered i.v. over a time period of approximately four to six
hours; during the infusion, serum potassium concentration
rose from 5.3 to 7.3 mEq/liter despite the fact that no
potassium was administered. The patient was discharged
on a regimen of phenytoin, cimetidine, and multivitamins.
He was readmitted for the eighth time three and one-hall
weeks later. Physical examination disclosed the following
findings: temperature, 36° C; pulse, 70; respirations, 18/
mm; blood pressure, 82/60mm Hg supine and 72/58 mm Hg
standing; weight, 63 kg; abdominal girth, 98 cm; the liver
edge was 5 cm below the right costal margin; there was
massive ascites and no peripheral edema; the patient was
mildly confused. Laboratory studies revealed the following
data: hematocrit, 35%; white blood cell count, 5,500/mm2.
Results of urinalysis revealed: specific gravity, 1.012; pH,
7.5; and occasional white blood cells. Electrolyte concen-
trations in the serum was sodium, 130 mEq; potassium, 2.8
mEq; and chloride, 66 mEq/liter. Total carbon dioxide
content was 49 mEq/liter. Arterial blood had a pH of 7.59,
with a Po2 of 53 mm Hg and a Pco2 of 47 mm Hg. The
BUN was 100 mg, serum creatinine was 5.8 mg, and
albumin was 2.2 g/i00 ml. Random samples for urinary
electrolytes were: sodium, 43 mEq; potassium, 42 mEq;
and chloride, 0 mEq/liter. The serum enzyme values were:
alkaline phosphatase, 8.9 Bodansky U; glutamic oxalo-
acetic transaminase (SGOT), 24 U; serum glutamic pyruvic
transaminase (SGPT), 11 U; lactate dehydrogenase
(LDH), 103 U; and creatinine phosphokinase (CPK), 3 U.
Chest X-ray film revealed elevated hemidiaphragms; an
electrocardiogram demonstrated normal rhythm at a rate of
70/mm, and there were nonspecific ST-T wave changes.
The patient was treated with a 500-mg sodium chloride
diet, salt-poor albumin, arginine hydrochloride (approxi-
mately 300 mEq/day, for three days), potassium chloride,
lactulose, cimetidine, and spironolactone (begun one week
later). The serum concentrations of potassium and chloride
rose (potassium, to 4.5 mEq; chloride, to 103 mEq), and
the total carbon dioxide content fell to 20 mEq/liter.
Eleven days following admission, the patient was alert
and oriented. Massive ascites persisted; abdominal girth
was 96 cm, and weight was 63 kg.
On the 12th hospital day, a LeVeen peritoneal-jugular
shunt was inserted because of the patient's severe ascites,
impaired renal function, and reluctance to use vigorous
diuretic therapy.
Preoperatively, the hematocrit was 32%, and the blood
chemistry values were: bilirubin, 2 mg; serum albumin, 3.3
g; BUN, 64 mg; serum creatinine, 1.9 mg/l00 ml; serum
sodium, 133 mEq; serum potassium, 3.9 mEq; serum chlo-
ride, 103 mEq; and total carbon dioxide content, 20 mEq/
liter.
For the first seven days postoperatively, the patient
received approximately 40 mg of furosemide and 50 mg of
spironolactone daily, but thereafter no diuretics were
given; while ingesting a 1-g sodium chloride diet, edema
did not recur. Blood pressure was 105/80 mm Hg, weight
was 58.6 kg, and abdominal girth was 84 cm. The serum
concentrations were: sodium, 135 mEq; potassium, 4.6
mEq; chloride, 103 mEq/liter. The total carbon dioxide
content 24 mEq/liter. The BUN was 19 mg, serum creati-
nine was 1.1 mg, and bilirubin was 1.2 mgIlOO ml. The
patient was discharged 17 days following surgery.
Discussion
It is an honor to inaugurate this new series of
conferences.
Ascites and renal failure are the key nephrological
problems presented by this patient. I shall devote
most of the discussion to these typical disorders of
advanced cirrhosis and the new form of management
undertaken in this case. The patient also developed a
number of interesting fluid and electrolyte distur-
bances related to his individual clinical course, and I
shall discuss some of these briefly.
We can discuss the patient's ascites and renal
failure together, since they began at about the same
time in his course and these problems probably are
related pathophysiologically. The patient had a num-
ber of episodes of reversible azotemia during the first
three years of his course here. I assume that these
episodes were prerenal azotemia due to the volume
depletion of vomiting. Each was associated with
metabolic alkalosis and a history of vomiting; renal
function became normal after treatment. Three
months before this admission, the patient was first
noted to have ascites, which increased in amount
thereafter despite treatment with a low-salt diet and
spironolactone. At the same time, moderately persis-
tent azotemia was first noted; during three admis-
sions thereafter, the serum creatinine concentration
only fell to 2.3, 3.9, and 1.9 mg/100 ml after treat-
ment. Although the patient was appropriately evalu-
ated at one point for causes of azotemia not directly
related to his cirrhosis, apparently no specific cause
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was found, such as ingestion of nephrotoxins, which
should always be considered in alcoholic patients.
The azotemia was not progressive and seems to
represent moderate, chronic renal failure, intrinsic to
his underlying liver disease.
The traditional view of the afferent mechanism for
this man's condition can be summarized as follows
(Fig. 1, left). Decreased albumin synthesis by the
cirrhotic liver reduces oncontic pressure, while intra-
hepatic obstruction raises hydrostatic pressure in the
hepatic and splanchnic circulation. These changes in
pressure alter Starling's forces to favor transudation
of plasma filtrate into the intraabdominal cavity. Re-
sistance to blood flow through the liver also traps an
increased volume of blood in the splanchnic circula-
tion. Both factors—trapping and transudation—dim-
inish the central "effective" blood volume. Renal
vasoconstriction, decreased renal blood flow, and
sodium retention are secondary to the reduction of
"effective" blood volume. Several conclusions rele-
vant to this man's management follow from this
formulation. Diuretics were used sparingly. Because
these agents act on the kidney, their direct effect is to
deplete the blood volume. Only if and when loss of
fluid from the plasma leads to a change in Starling's
forces in the hepatic/splanchnic circulation favoring
uptake of edema fluid (reduction in capillary pressure
and concentration of plasma proteins) will ascites
diminish and the blood volume be restored to its
initial, already inadequate, level. Thus, the well-rec-
ognized tendency for potent diuretics to precipitate
hypotension and renal failure is seen to be an iatro-
genic exacerbation of the fundamental patho-
physiological disorder, inadequate "effective" blood
volume. These complications also occur after para-
centesis and are explained, similarly, to be due
to further contraction of the "effective" circulatory
volume, when fluid shifts from the plasma to reform
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Fig. 2. LeVeen peritoneal-jugular shunt. Perforated silicone rub-
ber tubing bathes in ascitic fluid compartment. Spnnglike valve is
extrapentoneal and is connected to jugular vein by subcutaneous
silicone rubber tube. (Reprinted with permission of AMA [5].)
ascites. Based on this line of reasoning, some years
ago attempts were made to maintain intravascular
volume during diuresis by infusing ascites intrave-
nously. Dramatic diureses were often obtained, even
in patients otherwise resistant to diuretics, without
inducing hypotension or renal failure [1]. As a practi-
cal matter, this form of treatment is necessarily short
term.
In 1974 LeVeen and associates [2] described an
ingenious peritoneovenous shunt suitable for chronic
implantation by a minor surgical procedure under
local anesthesia. (Fig. 2) The key feature is a valve
which opens at a pressure of 3 to 5 cm of water. This
valve, implanted under the skin of the abdomen,
connects an intraabdominal drain to a subcutaneous
shunt, inserted in the jugular vein. Thus, when intra-
abdominal pressure exceeds venous pressure by 5
cm of water, ascites flows into the vein. If the rate of
self-infusion is too rapid, venous pressure will rise a
few centimeters and the valve will close, thereby
preventing overloading of the central circulation. A
Altered Starling's forces
in splanchnic circulation
Tubular sodium reabsorption and
I RBFand GFR
1
Decreased
"effective" blood volume
1
Tubular sodium reabsorption and
IRBF and GFR
Renal salt retention
Increased
"effective" blood volume
1
Altered Starling's forces
in splanchnic circulation
Ascites
Fig. 1. Simplified schemata of the 'undeifihling" (left) and
"overflow" (right) theories of the pathogenesis of the sodium
retention in cirrhosis.
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number of papers have described the effects of this
shunt [3, 4] in cirrhotics. Ascites is rapidly reab-
sorbed, and losses of 10 kg in ten days are reported in
patients previously refractory to diuretics [51. As-
cites was relieved in more than 95% of patients in
one large series [3], apparently indefinitely, although
detailed follow-up observations have not yet been
reported. The long-term effects on sodium retention
by the kidney, need for diuretics, and ability of
patients to tolerate increased sodium intake are as
yet unclear, although the originators state that they
have unpublished evidence that "avid reabsorption
of sodium in patients with refractory ascites can be at
least in part counteracted" [5]. Plasma aldosterone
and renin fall to normal [4, 5], but this observation
should not be taken to imply a cause and effect
relation to the accompanying natriuresis. At least
two groups [6, 7] have shown that volume expansion
can lower plasma aldosterone and renin in cirrhotics
with ascites, without inducing a natriuresis.
Although the point is not fully documented, it
appears that relief of ascites is obtained without the
adverse effects of hypovolemia, such as hypotension
and deterioration of renal function. Indeed, the
chronically reduced glomerular filtration rate (GFR)
characteristic of patients with advanced cirrhosis ac-
tually improves. In 28 patients, plasma creatinine
concentration decreased from 2.4 to 1.8 mg/100 ml
ten days after insertion of the shunt [5]. This im-
provement is presumably due to expanded central
volume, since similar increases in GFR occur after
infusion of ascites [1], and during bodily immersion
[8], which shift blood volume centrally. (The Le-
Veen shunt and paracentesis with reinlusion of as-
cites also lower intra-abdominal pressure, a maneu-
ver known to raise GFR acutely. The improvement
of GFR after reduction in abdominal pressure, how-
ever, doesn't persist, and the favorable effect of
immersion occurs without reduction in this pressure.
Thus, decreased abdominal pressure is probably not
the major mechanism for improved GFR after Le-
Veen shunting.)
Most strikingly, it is reported that hepatorenal
syndrome can be reversed by the LeVeen shunt.
Four cases have been presented in detail [4, 9], and
LeVeen et al [3] state that nine patients with the
syndrome all improved. The relation between chron-
ically reduced GFR in advanced cirrhosis and the
hepatorenal syndrome is uncertain. Although the for-
mer is common, only a minority of patients develop
the relentless progression of renal dysfunction to
oliguria and clinically significant renal failure that
characterizes the hepatorenal syndrome. It is not
known what fraction of those who develop the hepa-
torenal syndrome are patients who previously had
stable but reduced GFR for a prolonged period, and
what fraction are individuals with wholly normal
renal function who suddenly develop hepatorenal
syndrome. The apparent ability of the LeVeen shunt
to reverse these conditions for indefinite periods cer-
tainly suggests that both chronic reduction in GFR
and hepatorenal syndrome may be volume-depen-
dent phenomena. The familiar clinical observation
that hepatorenal syndrome may be triggered by mi-
nor hypovolemia, such as after paracentesis or a
small gastrointestinal hemorrhage, suggests a chroni-
cally inadequate effective" circulation, from which
irreversible renal failure can be generated by a small
added volume deficit. Acute volume expansion has
had limited, if any, benefit in patients with hepato-
renal syndrome [10]. More than ten years ago, one
study [11], however, showed maintained renal he-
modynamic and clinical benefit in a few patients
treated by reinfusion of ascites for several days. The
beneficial effects of the LeVeen shunt, the first prac-
tical method for chronic return of ascites to the
central circulation, fit with these limited previous
observations. The efferent mechanism of the effect is
unknown. It has recently been suggested that renal
failure in hepatorenal syndrome is due to the combi-
nation of increased vasoconstrictor (renin/angioten-
sin) and decreased vasodilator (prekallikrein/brady-
kinin) activity. As noted earlier, elevated plasma
angiotensin in the hepatorenal syndrome is de-
creased after insertion of the LeVeen shunt. The
effect of the shunt on plasma prekallikreinlbradyki-
nm is as yet unknown.
Should the patient under discussion have been
treated with a LeVeen shunt? He had massive as-
cites that had failed to respond to treatment with a
low-salt diet and spironolactone in-hospital or at
home. More potent agents had apparently been
avoided for fear of adverse effects, especially deteri-
oration of already diminished renal function. Thus,
this man cannot be described as resistant to a full
diuretic program, as were the patients treated with
the shunt in published series [3]. The dangers of
diuretic use are well known and include hypotension,
electrolyte disturbances (such as hyponatremia, po-
tassium depletion, and alkalosis), precipitation of
hepatic coma, and hepatorenal syndrome. As dis-
cussed earlier, it is uncertain whether patients with
chronic stable reduction of GFR, such as this man,
are more prone to hepatorenal syndrome, but as a
practical matter it is reasonable to be especially con-
cerned about further deterioration of renal function
in such patients. On the other hand, this patient's
azotemia was moderate (BUN, 64 mg/ 100 ml; serum
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creatinine, 1.9 mg/l00 ml) after initial in-hospital
management. Although firm data are difficult to find,
my own experience is that judicious, in-hospital use
of potent diuretics causes minor, easily treatable
complications, such as exacerbation of hyponatre-
mia or azotemia, in about 5% to 10% of patients with
cirrhosis and tense ascites. Severe complications,
such as clinical hypotension, severe encephalopathy,
serious deterioration of renal function, and hepato-
renal syndrome, can be avoided in all but 1% to 2%
of these patients by careful observation, slow di-
uresis not exceeding 1 kg of body-wt-los s/day, and
intermittent rather than continuous use of the most
potent agents such as furosemide. There is, of
course, an old-fashioned but effective alternative
treatment of tense ascites—paracentesis. When lim-
ited to removal of no more than 2 liters (sufficient,
because of the hyperbolic relation between intraab-
dominal pressure and volume, to reduce pressure
markedly), the risk of serious complications is low,
perhaps 1% in my experience.
The complications of the LeVeen shunt have been
reported, thus far, only by the originators [31, who
note approximately 5% wound infections, 3% sepsis,
15% leakage of ascites and 15% subcutaneous bleed-
ing. Ten percent of the patients develop upper gas-
trointestinal hemorrhage, presumably due to in-
creased pressure in varices as ascites is rapidly
reabsorbed, a familiar complication of rapid expan-
sion of blood volume in advanced cirrhosis. (Most of
the patients had bled previously, and the originators
suggest that the shunt should not be used after recent
variceal bleeding, unless a portosystemic shunt is
performed first.) Thus, the frequency of complica-
tions from the shunt is comparable to that from
careful use of diuretics, and probably exceeds that
from limited use of paracentesis. Moreover, further
complications from use of the shunt may appear after
more prolonged and extensive observation.
The other part of the cost-benefit equation must be
evaluated, however. Long experience indicates that
relief of severe ascites by low-salt diets, diuretics,
and paracentesis is limited and transient. Such relief,
obtained by careful management in the hospital, is
usually dissipated rapidly outside in the real world by
erratic control of diet and casual adherence to di-
uretic programs. The LeVeen shunt apparently pro-
duces dramatic relief of ascites for an indefinite pe-
riod in the majority of patients.
The question must be asked, however, why is
relief of ascites important? Since the underlying he-
patic dysfunction is not reversed, the greatly short-
ened life expectancy of patients with decompensated
cirrhosis will presumably not improve. The potential
benefits of decreased ascites are relief of fullness and
discomfort, improved appetite, and a greater sense
of well-being. An improved self-image may contrib-
ute to greater willingness to follow therapeutic regi-
mens, including abstinence from alcohol. Tense as-
cites may interfere with respiration, especially when
the patient is recumbent. Abdominal skin and umbili-
cal hernias may stretch excessively and break down.
Uncomfortable peripheral and scrotal edema may be
due, in part, to compression of the inferior vena cava
by tense ascites. Patients are often remarkably
asymptomatic, however, despite gross ascites.
Hence, the conservative view has been to accept
ascites, use cautious therapy to achieve the limited
goal of relief of symptoms when necessary, and to
avoid the frequent complications of attempts to pro-
duce a patient who is free of ascites.
The dramatic relief of ascites for indefinite periods
with the LeVeen shunt, however, is tempting to
physicians, such as me, who are frustrated by their
inability to alter the underlying, lethal hepatic pathol-
ogy. Moreover, the classical view that ascites is a
consequence of diminished "effective" circulation
suggests theoretical advantages for use of this proce-
dure, since intravascular volume is thereby continu-
ously restored to normal. Will this technique, for
example, prevent the hepatorenal syndrome, since
the initial reports cited above suggest it can treat this
otherwise irreversible and lethal complication? The
originators suggest that the incidence of hepatic en-
cephalopathy is reduced, perhaps because improved
renal function leads to a lower maintained level of
blood urea, thereby decreasing ammonia formation
from urea in the gut. They further report a markedly
improved sense of well-being, which may not be
entirely due to the psychological benefit of a surgical
procedure with a dramatic cosmetic effect. Wasting
of muscles and facies has long been recognized as
typical of cirrhotics with ascites—a big belly with
thin face and limbs—and usually has been attributed
to alcoholic malnutrition. The patient under discus-
sion had lost 16 kg of dry body weight over three
years. LeVeen and associates report rapid restora-
tion of muscle and fat and loss of the cirrhotic facies
within weeks after insertion of the shunt. Is there an
effect beyond improvement of appetite? Is there a
'cirrhotic cachexia" analogous to cardiac cachexia,
attributable to diminished "effective" circulation,
which can be overcome by chronic reinfusion of
ascites to the central volume? These are all exciting
possibilities suitable for careful study.
In terms of the management of individual patients
today, I would be conservative. In patients who
develop unequivocal hepatorenal syndrome, almost
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always irreversible and fatal with conventional treat-
ment, a trial of the LeVeen shunt seems indicated. (It
is important, of course, to rule out volume depletion
due to excessive diuresis and acute tubular necrosis,
both of which are frequent findings in patients with
cirrhosis and are often confused with hepatorenal
syndrome.) In patients who are symptomatic from
tense ascites that cannot be managed with diuretic
therapy, occasional paracentesis, and low-salt diets,
a trial of the shunt may be in order. The patient under
discussion had moderate, stable azotemia, but no
evidence of hepatorenal syndrome. It is not clear
whether he was symptomatic from ascites, but, in
any case, he had not been treated with potent diuret-
ics or paracentesis. Hence, I probably would not
have used the LeVeen shunt in this patient.
Whatever its ultimate place in the clinical treat-
ment of ascites, careful study of the effects of the
LeVeen shunt may make an important contribution
to our understanding of the pathophysiology of this
condition. Thus far, we have described the genesis of
ascites according to the conventional view, in which
renal sodium retention is secondary to underfilling of
the "effective" circulation. Recently, this view has
been challenged by clinical [12] and experimental
[13] evidence in favor of an "overflow" mechanism
(Fig. 1, right). According to this hypothesis, the sick
liver releases or stimulates factors which directly
cause renal vasoconstriction and excessive tubular
sodium reabsorption. Excess salt and water ulti-
mately "overflow" from the hepatic and splanchnic
circulation, where abnormal Starling's forces favor
transudation, to form ascites. The key difference
between the two hypotheses is whether the "effec-
tive" circulation is underfilled or overfilled, a point
with obvious consequences for the interpretation of a
variety of clinical phenomena in cirrhotic patients
with ascites. This is not the place for an extended
discussion of the arguments for each view, but a few
examples can be summarized. Numerous studies
show that blood volume is usually increased in pa-
tients with cirrhosis and ascites. This fits directly
with the "overflow" theory; the "underfilling" the-
ory explains this observation by postulating that
blood volume is increased because of increased vas-
cular capacity in the dilated splanchnic vessels, but
postulates that the (unmeasurable) "effective" circu-
lation is inadequately filled. Some studies show that
the rate of ascites formation does not increase after
paracentesis, nor does plasma volume decrease [121
as would be expected according to the traditional,
but not the "overflow" theory. Recently, Levy [13]
has provided strong evidence for the "overflow"
theory in cirrhotic dogs, in which he was able to
study the evolution of ascites through all stages. He
found that renal sodium retention preceded ascites
by ten days, that nonsplanchnic volume, measured
directly, was increased, and that paracentesis did not
cause re-formation of ascites as long as dietary salt
was restricted. Most pertinent to the present discus-
sion is Levy's finding [14] (LEVY, personal commu-
nication, 1978) that mobilization of ascites with a
LeVeen shunt does not eliminate renal sodium reten-
tion, although the natriuretic response to a diuretic is
greatly enhanced. When placed on a high-salt diet,
the cirrhotic dogs developed massive anasarca; al-
though strikingly, edema was now facial and pulmo-
nary, since the LeVeen shunt prevented the forma-
tion of significant ascites. These data obviously fit
easily in the "overflow" mechanism, but they are
difficult to reconcile with the conventional view.
Careful study of renal sodium-handling in patients
with LeVeen shunts should contribute significantly
to our understanding of the pathophysiology of as-
cites in man. The key point is whether patients
treated with the shunt will regain the ability to ex-
crete a normal dietary intake of sodium without di-
uretics. Although it has been reported that this was
the outcome in one patient [4], data on this point are
inadequate. Appropriate studies of the present pa-
tient would be very interesting.
Although this discussion has focused on the pa-
tient's principal clinical problem and its manage-
ment, brief comments on several other problems of
nephrological interest are in order. The patient had
hypokalemic alkalosis on several occasions, in each
episode related to vomiting. Use of diuretics such as
furosemide, a likely cause of this pattern in cirrhotics
with ascites, was apparently not a factor here. Al-
though mild hypokalemia, probably caused by poor
dietary intake of potassium and secondary aldostero-
nism, is sometimes present in patients with cirrhosis
and ascites, the alkalosis, the presence of the electro-
lyte abnormality on one occasion before ascites was
present, and on another occasion during treatment
with an aldosterone antagonist (assuming the patient
was taking it as prescribed!), all point to vomiting as
the princip1 cause of the hypokalemic alkalosis. At
first glance, the high urinary potassium (42 mEq/liter
on the last admission when serum potassium was 2.8
mEq/liter) may seem puzzling, since the usual teach-
ing is that urinary potassium should be below 20
mEq/liter when hypokalemia is caused by extrarenal
losses. Schwartz, van Ypersele de Strihou, and Kas-
sirer, however, have found that the pattern of uri-
nary electrolytes during the genesis of hypokalemic
alkalosis due to loss of gastric juice is different than
that characteristic of maintained hypokalemic alka-
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los is [15]. If we assume that this patient was vomit-
ing severely right up to the time of admission, the
pattern of urinary electrolytes would be typical of
that noted by Schwartz et a! during the genesis of
experimental hypokalemic alkalosis by gastric aspi-
ration. We can hypothesize that rapid loss of hydro-
chloric acid has elevated the patient's plasma bicar-
bonate above his renal tubular reabsorptive capacity,
even though the latter is presumably elevated by
volume contraction and possibly (to a lesser degree
than once believed) by hypercapnia. Hence, signifi-
cant bicarbonate escapes tubular reabsorption, as is
evident from the alkaline urine (pH, 7.5). This bicar-
bonate acts, in effect, as an unreabsorbable anion,
promoting delivery of sodium to the distal nephron
and, especially in the presence of secondary aldoste-
ronism, augmenting distal potassium secretion. The
ability of bicarbonate, acting as an unreabsorbable
anion, to force sodium excretion is especially striking
in this patient who, despite cirrhotic mechanisms
strongly favoring complete renal sodium retention,
exhibited a urinary sodium concentration of 60 mEq/
liter during one episode. At the same time, urinary
chloride was 0 mEq/liter, correctly signaling the un-
derlying state of sodium retentiveness. The forma-
tion stage of hypokalemic alkalosis due to vomiting is
one of the few instances in which the clinical use of
urinary sodium and potassium concentrations to sep-
arate renal from extrarenal losses of these ions may
prove invalid.
The deleterious consequences of hypokalemic
alkalosis in patients with cirrhosis are especially
worth noting. This patient on several occasions en-
tered with hepatic encephalopathy coincident with
the electrolyte derangement. The encephalopathy
cleared after a number of therapeutic maneuvers,
important among them being treatment to reverse the
hypokalemic alkalosis. It is well recognized that the
distribution of ammonia between extracellular fluid
and cells is determined, in part, by the hydrogen ion
gradient between them. Experimental and clinical
studies suggest that extracellular hypokalemic alka-
losis probably does not cause cellular alkalosis. In-
deed, the cells probably become more acid, espe-
cially if, as in the present patient, hypercapnia due to
respiratory compensation supervenes. The absolute
or relative acidification of the intracellular fluid, in-
cluding that of the brain, will trap an increased frac-
tion of the total body pool of ammonia inside cells.
Experimental evidence suggests that this is one
mechanism by which alkalosis may precipitate en-
cephalopathy. The other postulated mechanism is
renal. As is well known, potassium depletion stimu-
lates ammonia production by the kidney, presumably
in response to acidification of tubular cells. When
ammonia production increases during metabolic aci-
dosis, it is largely trapped by the acid urine. If,
however, extracellular alkalosis accompanies potas-
sium depletion, the urine will be relatively alkaline,
as in this patient. In this event, less ammonia will be
trapped in the urine, and more will diffuse into the
peritubular blood. These phenomena have been
demonstrated by renal venous catheterization in pa-
tients with cirrhosis. Moreover, as this patient dem-
onstrates, the compensatory hypoventilation of met-
abolic alkalosis may cause significant hypoxia, which
may contribute to the encephalopathy. (The esti-
mated alveolar-arterial P02 gradient in this patient,
however, was 35 to 40 mm Hg on two occasions,
indicating that his severe hypoxia was due to pulmo-
nary disease as well as hypoventilation.) Thus, it is
easy to see why hypokalemic alkalosis due to vomit-
ing or diuretics may precipitate encephalopathy and
justify treatment: increased ammonia production by
the kidney, increased movement of renal ammonia
into blood rather than urine, increased movement of
extracellular ammonia into brain cells, and hypoxia.
Moreover, elevation of plasma urea, because of as-
sociated prerenal failure as occurred in this patient,
may lead to increased intestinal ammonia production
through enhanced urea breakdown by bacterial flora
in the gut, as noted earlier.
Finally, a word should be included about the hy-
perkalemia precipated on one occasion by attempts
to treat the patient's severe alkalosis with arginine
hydrochloride. After infusion of 150 mEq of this
cationic amino acid, serum potassium concentration
rose 2 mEq/liter, from 5.3 to 7.3 mEq/liter. The
ability of all cationic amino acids to drive potassium
out of muscle cells is well documented both in vivo
and in vitro [161. At the time he received the infu-
sion, this patient was probably fully potassium-re-
pleted, since his serum potassium concentration was
5.3 mEqlliter despite extracellular alkalosis. He still
had reduced renal function, since even at discharge
serum creatinine concentration had fallen only to 3.8
mg/100 ml. The combination of sudden release of
potassium from tissues and limited renal excretory
capacity accounts for the sharp rise in serum potas-
sium. Similar increases were reported in several pa-
tients with advanced, chronic renal failure who were
infused with comparable amounts of arginine [161.
Questions and Answers
DR. J. T. HARRINGTON: We were reluctant to use
potent diuretics in this individual because on several
occasions in the past he had hepatorenal syndrome
or, at least, renal insufficiency associated with he-
100 Nephrology Forum
patic insufficiency. We attributed this reduction in
glomerular function in part to volume depletion, and
we thought that perhaps a reduction in "effective"
circulating volume was also responsible. On that
basis, the LeVeen shunt was attempted after many
hospitalizations U71. In the past when I have heard
you talk about treating patients admitted with cirrho-
sis, or at least hepatic decompensation, I seem to
recall that you have discouraged the use of potent
diuretics during that period. My question is, Are you
drawing a distinction between the use of potent di-
uretics shortly after admission and a week or two
later when the patient is stable?
DR. N. G. LEVINSKY: Perhaps I should clarify my
views on both points. First, with regard to the pres-
ence of hepatorenal syndrome, I can only reemphas-
ize what I said earlier. I would not feel there was
evidence that this patient had the hepatorenal syn-
drome. I would suggest that he had two types of
renal failure at different points in his course. On
many occasions, he was admitted with volume con-
traction due to vomiting and prerenal failure. Later
in his course when the azotemia persisted after fluid
repletion, I think he had chronic stable reduction in
renal hemodynamics and glomerular filtration; this is
seen in a significant fraction of patients with ad-
vanced cirrhosis who are not developing the hepato-
renal syndrome. As I said earlier, I am not even sure
that all those who develop the hepatorenal syndrome
necessarily have a creatinine of, perhaps, 1.5 or 2.0
mgIlOO ml for weeks or months and then deterio-
rate. In fact, my guess would be contrary; some start
with relatively normal renal blood flow and then
suddenly deteriorate. Thus, I think that distinctions
should be drawn between the various forms of renal
failure which are possible in the patient with cirrhosis
and advanced ascites. Second, I would not wish to
promulgate, in any way, the impression that I was
advocating the use of potent diuretics in all cirrhotics
with ascites. To clarify what I said, the physician
may feel treatment is needed when ascites is very
tense, skin is breaking down, breathing is labored, or
the patient is grossly disfigured and uncomfortable.
If he thinks relief of such symptoms is important in a
particular patient, the doctor might perform a modest
paracentesis or cautiously treat with potent diuretics,
to see if the patient is responsive. I would not have
used the shunt just yet in this patient because I think
it is as safe to give a few doses of furosemide to see
what kind of response you get, as it is to insert the
shunt.
DR. J. T. HARRINGTON: You estimated earlier that
the incidence of severe complications from intermit-
tent use of potent diuretics is 1% to 2%. Is it possible
that severe diuretic-induced complications are more
likely in patients with preexisting renal insufficiency,
than in patients with normal renal function?
DR. N. G. LEVINSKY: It sounds reasonable but I
don't know.
DR. J. J. COHEN: Would you comment on the
strategy of using intermittent albumin infusion cou-
pled with diuretics as an alternative therapeutic ap-
proach to management of ascites when it is deemed
to be necessary?
DR. N. G. LEVINSKY: Like ascites reinfusion, al-
bumin avoids blood volume depletion and increases
the response to diuretics. Either may precipitate
bleeding from varices or hepatic encephalopathy. If
the hospital is appropriately equipped, I would favor
ascites reinfusion because ascites is relieved directly.
In practice, we rarely use either technique.
DR. J. J. COHEN: That leads me to the next ques-
tion. If one adopts the "overflow" hypothesis to
account for the sodium retention, how would one
explain the apparent diuresis that usually ensues
after insertion of the shunt?
DR. N. G. LEVINSKY: I think there is no problem
as long as the sodium retention is not completely
reversed. According to the "overflow" theory, cir-
rhosis directly stimulates sodium retention, which
should not disappear unless the cirrhosis itself im-
proves. The critical question is whether the patient is
able to handle a normal sodium intake without any
need for diuretics. If he is able to handle a wide range
of sodium intakes, it would be evidence against the
"overflow" hypothesis. But as long as you must give
him any diuretics or reduce his salt intake, the find-
ings would be perfectly compatible with the thesis
that renal sodium retention is stimulated by a direct
hepatic mechanism, which has not been reversed by
the shunt.
DR. J. T. HARRINGTON: Actually, we don't know
the sodium tolerance of the patient. He was given
diuretics following the shunt prophylactically be-
cause of our lack of experience in handling such
patients, and, for the same reason, he was given a 1-g
salt diet. He has not had a sodium challenge.
DR. J. P. KASSIRER: With regard to some of the
issues you raised about metabolic alkalosis, perhaps
there are some points worth making. First, I think
your description of the difference in the composition
of the urine between the nonsteady state and the
steady state in patients with gastric alkalosis is quite
accurate. We would have no quarrel with your physi-
ologic analysis including the fact that a stimulus for
sodium reabsorption is necessary in order to pre-
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serve bicarbonate reabsorption when a patient be-
comes hypochioremic and alkalotic, and that volume
contraction is the factor that creates that stimulus.
Certainly, when metabolic alkalosis is first develop-
ing or becoming more severe, that stimulus is lack-
ing, and that is the reason for the sodium and alkali
diuresis. This sequence was shown nicely in experi-
ments with normal human subjects in which meta-
bolic alkalosis was induced by selective depletion of
hydrochloric acid [18]. The experience in patients
with vomiting and nasogastric suction confirms this
experimental observation because most of these pa-
tients have a fair amount of sodium and bicarbonate
in their urine and the urine pH is typically high [19].
By contrast, the patient with metabolic alkalosis who
is in a steady state has no sodium or alkali in the
urine and, of course, the urine is acid. Second,
metabolic alkalosis may be particularly deleterious
for a patient with cirrhosis. The best evidence sug-
gests that, of the many factors that have been in-
voked as responsible for hepatic encephalopathy,
blood pH is one that seems to correlate fairly well
with the level of awareness. Several studies show
that a considerably larger fraction of patients with
encephalopathy are alkalemic compared to those
with normal central nervous system function [20].
Patients with cirrhosis may be uniquely at risk when
they develop metabolic alkalosis because they often
have a simultaneous mild respiratory alkalosis, the
mechanism for which is not clear. Therefore, for any
given elevation of bicarbonate concentration, cir-
rhotics tend to be more alkalemic than the noncir-
rhotic individual. The normal adaptive respiratory
response to metabolic alkalosis is not well-defined,
but it appears that every increase in plasma bicar-
bonate of 1 mEq/liter is associated with an increase
in aiteiial Pco2 of approximately 0.6 to 0.9 mm Hg.
On two of the occasions that severe hyperbicarbona-
temia occurred in this patient, the increment in arte-
rial Pco2 was only approximately 0.3 to 0.5 mm Hg
per mEq/liter increment in bicarbonate, suggesting
that hyperventilation was contributing to alkalemia.
Unfortunately, we don't know whether or not the
patient was hypocapnic in the absence of metabolic
alkalosis. Third, I have a final observation about
your remark that patients with the LeVeen shunt
seem to develop encephalopathy less frequently.
One explanation that might account for this finding is
that these patients are no longer being subjected to
potent diuretics and, therefore, are not developing
potassium depletion, volume contraction, and meta-
bolic alkalosis, all factors that might predispose them
to develop cerebral dysfunction.
DR. D. BERNARD (University Hospital, Boston):
Could you comment specifically on the use of spiron-
olactone? The British literature has placed tremen-
dous emphasis on the value of inhibiting steroid
effects. A couple of years ago, it was suggested that
the dose of spironolactone be titrated against the
sodium and potassium concentrations in the urine
aiming for a ratio of one. You haven't discussed
which diuretics you would recommend, but do you
think spironolatone actually adds anything to diuretic
therapy?
DR. N. G. LEVINSKY: Yes, spironolactone is often
used initially, and I think properly, because it is a
relatively modest diuretic and, hence, is unlikely to
cause some of the adverse effects of rapid volume
contraction produced by the more potent agents such
as furosemide. I think one should always start with a
less potent agent. A second advantage is that it
doesn't induce potassium depletion and alkalosis
and, thus, some of the encephalopathic complica-
tions. Beyond that, I don't think it has any specific
virtue. I noted earlier that two studies quite clearly
separate reduction of plasma aldosterone from natri-
uresis in cirrhosis. I don't think there is any specific
virtue in competing with aldosterone. Spironolac-
tone is a good baseline diuretic which may mitigate
the hypokalemia and alkalosis that occurs if you
must use one of the more potent diuretics.
RENAL FELLOW: You suggested doing paracen-
tesis to remove 1 or 2 liters of fluid. Gabuzda has
estimated that the formation of ascitic fluid occurs at
approximately 800 cc per 24 hours [21]. Given the
same Starling's forces, wouldn't ascites simply reac-
cumulate in a few days thereby mitigating the treat-
ment? In addition, isn't the risk of spontaneous peri-
tonitis in the alcoholic—estimated at 10% to 15% by
some authorities—worth consideration?
DR N. G. LEVINSKY: Yes, the latter is a very good
point. I should have listed spontaneous peritonitis as
a complication of ascites, although I think 10% to
15% is a generous estimate. With regard to your first
point, you may have noticed that I made a contrary
statement earlier: I pointed out that the Reynolds
group did not find an increased rate of formation of
ascites after paracentesis. The Reynolds group com-
mented that the discrepancy could be attributed to
sodium restriction in their patients, while Gabuzda's
patients were not sodium restricted. If one accepts
the "overflow" hypothesis, this is a critical point.
According to the "overflow" hypothesis, the patient
will not rapidly reform ascites on a low-salt diet,
because ascites formation is secondary to renal salt
retention.
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DR. J. J. COHEN: One of the striking occurrences
in this patient was the hyperkalemia precipitated by
the arginine infusion. I wonder whether you think
arginine should be avoided as a treatment for meta-
bolic alkalosis in favor of hydrochloric acid, which
has been recommended by some.
DR. N. G. LEvIN5Ky: There are other reasons to
favor hydrochloric acid, but hyperkalemia is not a
major problem if you are aware of it. I would admin-
ister the arginine slowly and check the serum potas-
sium after concentration an hour or two.
RENAL FELLOW: Are there any instances of pul-
monary edema following insertion of the shunt?
DR. N. G. LEvIN5KY: None have been reported,
but I would add that most of the reports describe
experiences occurring within the first ten days after
surgery. Most importantly, during that time the pa-
tients received diuretics, and dietary salt was re-
stricted. The dogs who developed pulmonary edema,
described earlier, were not receiving diuretics
or a low-salt diet. According to the experimental
results, extraabdominal edema might occur if pa-
tients with LeVeen shunts are taken off diuretics and
placed on ad lib salt intake.
Reprint requests to Dr. Norman Levinsky, University Hospital,
75 E. Newton St., Boston, Massachusetts 02118, U.S.A.
References
1. EKNOYAN 0, MARTINEZ-MALDONADO M, YLUM JJ, Suici
WN: Combined ascitic-fluid and furosemide infusion in the
management of ascites. N EnglJ Med 282:713—717, 1970
2. LEVEEN RH, CHRisTounlAs 0, MOON IP, LUFT R, FALK 0,
OROSBERG 5: Peritoneovenous shunting for ascites. Ann Surg
180:580—590, 1974
3. LEVEEN RH, WAPNICK 5, GROSBERG 5, KINNEY MJ: Fur-
ther experiences with peritoneovenous shunt for ascites. Ann
Surg 184:574—579, 1976
4. WITTE MH, WITTE CL, JACOBS 5, KUT R: Peritoneovenous
(LeVeen) shunt. JAMA 239:31—33, 1978
s. WAPNICK s, GR05BERG s, KINNEY MJ, LEVEEN FIR: Le-
Veen continuous peritoneal-jugular shunt. JAMA 237:13 1—
133, 1977
6. CHONKO AM, BAY WH, STEIN JH, FERRIS TF: The role of
renin and aldosterone in the salt retention of edema. Am J
Med 63:881—889, 1977
7. EPSTEIN M, LEVINSON R, SANCHO J, HABER E, RE R:
Characterization of the renin-aldosterone system in decom-
pensated cirrhosis. Circ Res 41:818—829, 1977
8. EPSTEIN M, PINS DS, SCHNEIDER N, LEVINSON R: Determi-
nantS of deranged sodium and water homcostasis in decom-
pensated cirrhosis. J Lab Clin Med 87:822—839, 1976
9. FULLEN wD: Hepatorenal syndrome: Reversal by perito-
neovenous shunt. Surgery 82:337—341, 1977
10. CONN HO: A rational approach to the hepatorenal syndrome.
Gastroenterology 65:321—340, 1973
11. TRISTANI FE, COHN JN: Systemic and renal hemodynamics
in oliguric hepatic failure: Effect of volume expansion. J Clin
Invest 46:1894—1906, 1967
12. LIEBERMAN FL, DENISON EK, REYNOLDS TB: The relation-
ship of plasma volume, portal hypertension, ascites and renal
sodium retention in cirrhosis: The overflow theory of ascites
formation. Ann NYAcad Sci 170:202—206, 1970
13. LEVY M: Sodium retention and ascites formation in dogs with
experimental portal cirrhosis. Am J Physiol 233:F572—F585,
1977
14. Lavv M, WExLER MJ: Urinary sodium retention and the
"effective" plasma volume in dogs with experimental cirrho-
sis and ascites (abstr.). Clin Res 25:706A, 1977
15. SCHWARTZ WB, VAN YPERSELE DE STRIHOU C, KA55IRER
JP: Role of anions in metabolic alkalosis and potassium defi-
ciency. N EngI J Med 279:630—639, 1968
16. HERTZ P, RICHARDSON JA: Arginine-induced hyperkalemia
in renal railurc patients. Arch Intern Med 130:778—780, 1972
17. PLAD5ON TR, PARRISH RM; Hepatorenal syndrome: Recov-
ery after peritoneovenous shunt. Arch Intern Med 137:1248—
1249, 1977
18. KA55IRER JP, SCHWARTZ WB: The response of normal man
to selective depletion of hydrochloric acid: Factors in the
genesis of persistent gastric alkalosis. Am J Med 40:10—26,
1966
19. HOWE CT, LEQUESNE LP: Pyloric stenosis: The metabolic
effects. BrJ Surg 51:923—932, 1964
20. CASEY TH, SUMHERSKILL WHJ, BICKPORD RU, RO5EVEAR
JW: Body and serum potassium in liver disease: II. Relation-
ship to arterial ammonia, blood pH, and hepatic coma. Gas-
troenterology 48:208—215, 1965
21. GABUZDA OH: Cirrhosis, ascites, and edema. Gastroenterol-
ogy 58:546—553, 1970
